Interim report
Page 1
- 1 - Consolidated Financial Results for the Nine Months Ended September 30, 2026 (Under Japanese GAAP) November 2, 2026 Company name CREATE MEDIC CO., LTD. Stock exchange listings：Tokyo Standard Securities code 5187 URL https://www.createmedic.co.jp/english/ Representative Osamu Imazawa President Inquiries Teruya Ueno Executive Officer, General Manager of Corporate Planning Department Dividend payable date (as planned) ：― Supplemental material of results：Yes, only in Japanese Convening briefing of results ：None (Yen amounts are rounded down to millions, unless otherwise noted.) 1. Consolidated financial results for the nine months ended September 30, 2026 (from January 1, 2026 to September 30, 2026) (1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.) Net sales Operating profit Ordinary profit Profit attributable to owners of parent Nine months ended Millions of yen % Millions of yen % Millions of yen % Millions of yen % September 30, 2026 10,467 4.1 509 (44.2) 568 (34.8) 301 (54.7) September 30, 2025 10,054 5.7 913 75.3 871 59.9 666 (10.5) Note: Comprehensive income For the nine months ended September 30, 2026：699 Millions of yen (82.8%) For the nine months ended September 30, 2025：382 Millions of yen ((57.0)%) Basic earnings per share Diluted earnings per share Nine months ended Yen Yen September 30, 2026 37.05 33.30 September 30, 2025 78.45 76.57 (2) Consolidated financial position Total assets Net assets Capital adequacy ratio Net assets per share As of Millions of yen Millions of yen % Yen September 30, 2026 19,831 16,148 81.4 2,028.71 December 31, 2025 20,143 16,332 81.1 1,947.68 Reference: Owner's equity As of September 30, 2026 16,147 Millions of yen As of December 31, 2025 16,331 Millions of yen 2. Cash dividends Annual dividend First quarter Second quarter Third quarter Year end Annual Yen Yen Yen Yen Yen Fiscal year ended December 31, 2025 － 17.00 － 28.00 45.00 Fiscal year ending December 31, 2026 － 20.00 － Fiscal year ending December 31, 2026 (Forecast) 27.00 47.00 Note: Revisions to the forecast of cash dividends most recently announced：None
Page 2
- 2 - 3. Consolidated financial forecast for the fiscal year ending December 31, 2026 (from January 1, 2026 to December 31, 2026) (Percentages indicate year-on-year changes.) Net sales Operating profit Ordinary profit Profit attributable to owners of parent Basic earnings per share Fiscal year ending Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen December 31, 2026 13,960 2.5 760 (24.4) 800 (19.0) 560 (21.5) 68.90 Note: Revisions to the earnings forecasts most recently announced：None * Notes (1) Significant changes in the scope of consolidation during the period：None (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements：None (3) Changes in accounting policies, changes in accounting estimates, and restatement (i) Changes in accounting policies due to revisions to accounting standards and other regulations ：None (ii) Changes in accounting policies due to other reasons ：None (iii) Changes in accounting estimates ：None (iv) Restatement ：None (4) Number of issued shares (common shares) ① Number of issued and outstanding shares at the period end (including treasury stock) As of September 30, 2026 9,664,327 shares As of December 31, 2025 9,664,327 shares ② Number of treasury stock at the period end As of September 30, 2026 1,704,726 shares As of December 31, 2025 1,279,220 shares ③ Average number of shares (quarterly period- YTD) Nine months ended September 30, 2026 8,146,383 shares Nine months ended September 30, 2025 8,497,339 shares * Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm：None * Proper use of earnings forecasts, and other special matters Caution Regarding Forward-Looking Statements: The forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable. They are not intended as a promise by the Company that they will be achieved, and actual results may differ significantly due to various factors.